2026– date –
-
Eli Lilly Acquires AtaiBeckley to Accelerate Phase III Development of BPL-003 for Treatment-Resistant Depression and Mental Health
Eli Lilly and Company USA Overview Eli Lilly announced the acquisition of AtaiBeckley to accelerate the development of therapies for treatment-resistant depression (TRD) and other mental health conditions. AtaiBeckley's lead candidate, B... -
How Gene Therapies Get to Patients Faster: Liv Hospital Explores FDA’s Expedited Pathways
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive article clarifying the U.S. FDA's expedited approval pathways for gene therapies, focusing on Breakthrough Therapy Designation and Accelerated Approval. These crucia... -
FDA Seeks Input on Psychedelic Drug Therapeutic Use: Exploring Psilocybin and MDMA for Depression and PTSD
RAPS USA Overview The U.S. FDA is soliciting public input on the potential therapeutic uses of psychedelic drugs, specifically psilocybin for depression and MDMA-assisted therapy for PTSD. While the FDA granted Breakthrough Therapy Desig... -
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Beyond the Liver: Engineered LNPs Achieve Precision Cardiac Delivery for SCD1 Inhibitor Aramchol
PR Newswire Israel Overview Galmed, in collaboration with Barcode Nanotech, has developed a groundbreaking lipid nanoparticle (LNP) formulation that precisely redirects its SCD1 inhibitor, Aramchol, from liver hepatocytes to cardiac musc... -
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Focused Ultrasound Blood-Brain Barrier Opening: Remote Metabolic Response Discovered in Primate Brain Raises Clinical Application Challenges
PubMed (National Library of Medicine) USA Overview Low-intensity focused ultrasound (LIFU) is a promising technology for blood-brain barrier (BBB) opening for drug delivery, yet a study in non-human primate models revealed unexpected rem... -
FDA Approval a TPD Turning Point? Maria Soloveychik Cautions Single Molecule Success Doesn’t Guarantee All Targets
Drug Discovery Online USA Overview Maria Soloveychik acknowledges the FDA approval of a bivalent degrader as a crucial 'proof point' for the Targeted Protein Degradation (TPD) field but warns that this single molecular success does not n... -
Oral GLP-1 Market Shift: Foundayo (orforglipron) Gains FDA Approval After Oral Wegovy, Demonstrating Dosing Convenience Advantage
GoodRx Health USA Overview The oral GLP-1 receptor agonist market sees a new entrant as Foundayo (orforglipron) received FDA approval on April 1, 2026, becoming the second oral GLP-1 therapy after oral Wegovy (semaglutide). Foundayo offe...
